The discrete charm of oncolytic viruses: Toward the finish line

IF 48.8 1区医学 Q1 CELL BIOLOGY

Cancer Cell Pub Date : 2025-03-27 DOI:10.1016/j.ccell.2025.03.010

Pedro R. Lowenstein, Maria Luisa Varela, Maria G. Castro

引用次数: 0

Abstract

Oncolytic viruses (OVs) are being optimized to treat cancer, including brain, ovarian, lung, and pancreatic tumors. Recent advances include replicating adenoviruses and herpes simplex virus 1 (HSV-1) armed with therapeutic transgenes, combined with serial injections and systemic delivery via retargeting, as achieved for adeno-associated virus 9 (AAV9). Clinical trials are showing promising efficacy. Here, we summarize the advancements and challenges associated with OV-based cancer therapies and discuss their mechanisms of action and strategies for enhancing the efficacy of OV treatments.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Cell 医学-肿瘤学

CiteScore

55.20

自引率

1.20%

发文量

179

审稿时长

4-8 weeks

期刊介绍： Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows: Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers. Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice. Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers. Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies. Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.